Recent developments to share with you

Our Company Hires Professors in Pharmaceutics and Pharmaceutical Analysis from China Pharmaceutical University as Technical Advisors

2022-09-12


Our R&D team has more than 30 members, primarily consisting of formulation, analysis, R&D QA, finance, and logistics support departments. All core R&D personnel graduated from China Pharmaceutical University with degrees in pharmacy-related fields. The company has hired professors specializing in pharmaceutics and pharmaceutical analysis from China Pharmaceutical University to serve as technical advisors, helping to solve complex technical challenges in our projects.

We currently have over 20 ongoing R&D projects, with more than 50% already under technology transfer or technology cooperation agreements. In 2017, the total value of technology transfer contracts exceeded RMB 10 million. Our team has strong R&D capabilities.

Keywords:

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03